Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®
Status:
Completed
Trial end date:
2017-12-22
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate relative bioavailability between 80 mg LY03005
oral tablets and 50 mg Pristiq® oral tablets after a single dose of each drug in a cross-over
2-period design under fasting condition in healthy subjects between 18 and 50 years of age.
Phase:
Phase 1
Details
Lead Sponsor:
Luye Pharma Group Ltd.
Treatments:
Desvenlafaxine Succinate Molecular Mechanisms of Pharmacological Action Neurotransmitter Agents Neurotransmitter Uptake Inhibitors Serotonin and Noradrenaline Reuptake Inhibitors